» Articles » PMID: 24454973

Clinical Associations of Human T-Lymphotropic Virus Type 1 Infection in an Indigenous Australian Population

Overview
Date 2014 Jan 24
PMID 24454973
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In resource-poor areas, infectious diseases may be important causes of morbidity among individuals infected with the Human T-Lymphotropic Virus type 1 (HTLV-1). We report the clinical associations of HTLV-1 infection among socially disadvantaged Indigenous adults in central Australia.

Methodology And Principal Findings: HTLV-1 serological results for Indigenous adults admitted 1(st) January 2000 to 31(st) December 2010 were obtained from the Alice Springs Hospital pathology database. Infections, comorbid conditions and HTLV-1 related diseases were identified using ICD-10 AM discharge morbidity codes. Relevant pathology and imaging results were reviewed. Disease associations, admission rates and risk factors for death were compared according to HTLV-1 serostatus. HTLV-1 western blots were positive for 531 (33.3%) of 1595 Indigenous adults tested. Clinical associations of HTLV-1 infection included bronchiectasis (adjusted Risk Ratio, 1.35; 95% CI, 1.14-1.60), blood stream infections (BSI) with enteric organisms (aRR, 1.36; 95% CI, 1.05-1.77) and admission with strongyloidiasis (aRR 1.38; 95% CI, 1.16-1.64). After adjusting for covariates, HTLV-1 infection remained associated with increased numbers of BSI episodes (adjusted negative binomial regression, coefficient, 0.21; 95% CI, 0.02-0.41) and increased admission numbers with strongyloidiasis (coefficient, 0.563; 95% CI, 0.17-0.95) and respiratory conditions including asthma (coefficient, 0.99; 95% CI, 0.27-1.7), lower respiratory tract infections (coefficient, 0.19; 95% CI, 0.04-0.34) and bronchiectasis (coefficient, 0.60; 95% CI, 0.02-1.18). Two patients were admitted with adult T-cell Leukemia/Lymphoma, four with probable HTLV-1 associated myelopathy and another with infective dermatitis. Independent predictors of mortality included BSI with enteric organisms (aRR 1.78; 95% CI, 1.15-2.74) and bronchiectasis (aRR 2.07; 95% CI, 1.45-2.98).

Conclusion: HTLV-1 infection contributes to morbidity among socially disadvantaged Indigenous adults in central Australia. This is largely due to an increased risk of other infections and respiratory disease. The spectrum of HTLV-1 related diseases may vary according to the social circumstances of the affected population.

Citing Articles

Characterising airway inflammation in Aboriginal and Torres Strait Islander and non-Aboriginal and Torres Strait Islander adults with asthma and COPD.

Young N, Chen W, Chatterjee S, Gelzinnis S, Latheef A, Simpson J BMJ Open Respir Res. 2025; 12(1).

PMID: 39986687 PMC: 11848662. DOI: 10.1136/bmjresp-2024-002619.


ITGAM-macrophage modulation as a potential strategy for treating neutrophilic Asthma: insights from bioinformatics analysis and in vivo experiments.

Yan Q, Liu Z, Chen Y, Zhang X, Zheng W, Liu X Apoptosis. 2023; 29(3-4):393-411.

PMID: 37950848 DOI: 10.1007/s10495-023-01914-5.


HTLV-1 as a contributing factor towards scabies and its systemic sequelae.

Cockbain B, Rosadas C, Taylor G J Glob Health. 2023; 13:03057.

PMID: 37921043 PMC: 10623376. DOI: 10.7189/jogh.13.03057.


The 'ABC' of respiratory disorders among adult Indigenous people: asthma, bronchiectasis and COPD among Aboriginal Australians - a systematic review.

Howarth T, Jersmann H, Majoni S, Mo L, Ben Saad H, Ford L BMJ Open Respir Res. 2023; 10(1).

PMID: 37451702 PMC: 10351270. DOI: 10.1136/bmjresp-2023-001738.


abscess mimicking sarcoma in a HTLV-1-infected Indigenous Australian man: Case report and literature review.

Susanto M, Dunning J, Chew R Clin Case Rep. 2023; 11(5):e7351.

PMID: 37215972 PMC: 10196424. DOI: 10.1002/ccr3.7351.


References
1.
Murphy E, Wilks R, Morgan O, Hanchard B, Cranston B, Figueroa J . Health effects of human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort. Int J Epidemiol. 1996; 25(5):1090-7. DOI: 10.1093/ije/25.5.1090. View

2.
Sugisaki K, Tsuda T, Kumamoto T, Akizuki S . Clinicopathologic characteristics of the lungs of patients with human T cell lymphotropic virus type 1-associated myelopathy. Am J Trop Med Hyg. 1998; 58(6):721-5. DOI: 10.4269/ajtmh.1998.58.721. View

3.
Einsiedel L, Fernandes L, Woodman R . Racial disparities in infection-related mortality at Alice Springs Hospital, Central Australia, 2000--2005. Med J Aust. 2008; 188(10):568-71. DOI: 10.5694/j.1326-5377.2008.tb01791.x. View

4.
Mori S, Mizoguchi A, Kawabata M, Fukunaga H, Usuku K, Maruyama I . Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers. Thorax. 2005; 60(2):138-43. PMC: 1747290. DOI: 10.1136/thx.2004.021667. View

5.
Stuver S, Tachibana N, Okayama A, Mueller N . Evaluation of morbidity among human T lymphotropic virus type 1 carriers in Miyazaki, Japan. J Infect Dis. 1996; 173(3):584-91. DOI: 10.1093/infdis/173.3.584. View